Clearmind Signs Definitive $2.5M Deal for 51% of EV Wireless Charging Firm
CMND sits 55% above its 52-week low of $1.43 on light trading volume (0.1× avg).
Summary
Clearmind Medicine signed a definitive agreement to acquire 51% of Charging Robotics for $2.5 million and provide a $1.5 million loan, closing expected the week of September 7, 2026.
Key Events · M&A and Partnerships · CMND
-
Definitive 51% Acquisition Signed
Clearmind entered a share purchase agreement on August 31, 2026 to buy 149 ordinary shares of Charging Robotics for $2.5 million ($16,778 per share), representing 51% of the Israeli company on a fully diluted basis.
-
$1.5M Loan at 4% Interest
As a condition to closing, Clearmind will lend Charging Robotics $1.5 million at 4.0% simple interest, due on the third anniversary with automatic extension until Charging Robotics generates positive cash flow.
-
Total Commitment vs. Market Cap
The combined $4.0 million equity purchase and loan exceeds Clearmind's approximately $2.5 million market cap, a significant capital deployment for a company with a going-concern warning.
-
Closing Expected Week of September 7
Closing is expected during the week of September 7, 2026, subject to customary conditions including execution and funding of the loan agreement.
Analysis · CMND · Life Sciences
Clearmind converted its August 3 non-binding letter of intent into a definitive agreement to acquire 51% of Charging Robotics for $2.5 million, plus a $1.5 million loan at 4% interest. The deal diversifies a clinical-stage biotech into EV wireless charging infrastructure, but the $4 million total commitment is substantial relative to Clearmind's roughly $2.5 million market cap and comes amid a going-concern warning and recent discounted convertible-note financings. The loan's automatic extension if Charging Robotics lacks positive cash flow means Clearmind may not see repayment for years.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 29.9% of the 1988 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $2.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $1.43 to $524.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.